Orexo AB (publ) (ORXOF OTCQX) stock market data APIs
$2.0967
0(0%)
as of May 11, 2026
Try our APIs with
free plan!
Orexo AB (publ) Financial Data Overview
Price chart is built with
Anychart
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Prev. Close
2.0967
Open
2.0967
High
2.0967
Low
2.0967
52 wk Range
1.08-3.23
Market Cap
73 767 K
Shares Outstanding
35 127 K
Revenue
544 M
Beta
0.873
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Orexo AB (publ) data using free add-ons & libraries
Get Orexo AB (publ) Fundamental Data
Orexo AB (publ) Fundamental data includes:
- Net Revenue: 544 M
- EBITDA: -303 300 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-28
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Orexo AB (publ) News
New
Orexo postpones publication of the Annual Report
UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The previously anno...
Notice of Annual General Meeting of Orexo
UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held o...
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
OX124 is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Nine out of ten fatal opioid overdoses in the US involve synthetic opioids If approved, the US launch...
Orexo Interim Report Q4 2022, incl. Full Year Report
UPPSALA, Sweden, Jan. 26, 2023 /PRNewswire/ -- Important steps forward in a challenging environment Q4 2022 highlights Total net revenues of SEK 156.1 m (144.0) EBITDA of SEK -53.1 m (-48.5), EBI...
Get Orexo AB (publ) fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
